Double-Barreled antibody attack aims to wipe out hidden myeloma cells
NCT ID NCT06993675
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether two bispecific antibody drugs, talquetamab and teclistamab, can eliminate remaining cancer cells in newly diagnosed multiple myeloma patients who still have detectable disease after initial treatment. About 50 participants will receive talquetamab first, and if that doesn't clear the cancer, they may switch to teclistamab. The goal is to achieve minimal residual disease (MRD) negativity, a deep remission state linked to better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Talquetamab and teclistamab (bispecific antibodies)
- What this could lead to
- If successful, this approach could help more patients achieve deep remission after initial therapy, potentially delaying relapse and improving long-term outcomes.
- What could go wrong
- This is a small Phase 2 trial with only 50 participants, so results may not apply to all patients. Bispecific antibodies can cause serious side effects like cytokine release syndrome, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wilmot Cancer Center, Clinical Trial Office of the University of Rochester Medical Center
NOT_YET_RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact